Professional Hemophilia Resources
Hemophilia A Treatment Reimbursement
CSL Behring provides a range of reimbursement services for hemophilia A patients,
including individual claims processing reviews, assistance in appeals, insurance
investigations into product coverage, and prior approvals for therapies authorization.
To speak with a representative, call the Reimbursement Answerline at 1-800-676-4266
Monday through Friday from 8 a.m. to 5 p.m. ET. Or, visit our online Reimbursement Resource Center.
BILLING CODES
|
J-7192- FACTOR VIII (ANTIHEMOPHILIC FACTOR RECOMBINANT), PER IU
|
286.0 - CONGENITAL FACTOR
VIII DISORDER
|
96374
96376
96365
|
This hemophilia resource provides information from a complex and evolving medical
coding system. The treating physician is solely responsible for diagnosis coding
and determination of the appropriate ICD-9-CM codes that describe the hemophilia
A patient’s condition and are supported by the medical record. All codes listed
in this guide are for informational purposes and are not an exhaustive list. The
CPT, HCPS, and ICD-9-CM codes provided are based on AMA or CMS guidelines. The billing
party is solely responsible for coding of services (eg, CPT coding). Because government
and other third-party payor coding requirements change periodically, please verify
current coding requirements directly with the payor being billed.
NDC CODES
|
NDC 0053-8131-02
|
Approximately 250 IU per bottle
|
|
NDC 0053-8132-02
|
Approximately 500 IU per bottle
|
|
NDC 0053-8133-02
|
Approximately 1000 IU per bottle
|
|
NDC 0053-8134-02
|
Approximately 2000 IU per bottle
|
|
NDC 0053-8135-02
|
Approximately 3000 IU per bottle
|
Clinical literature
The following Clinical Literature is available to order today:
- Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious
for Treatment of Hemophilia A in Home Therapy. Abshire TC et al., 2000.
- Children’s Preferences of Transfer Devices for Reconstitution of Factors VIII
and IX for the Treatment of Haemophilia. Khair K. Haemophilia 2009.
- Full-length Sucrose-formulated Recombinant Factor VIII for Treatment of Previously
Untreated or Minimally Treated Young Children with Severe Haemophilia A. Kreuz
W et al.; Thromb Haemost 2005.
- Prophylaxis Versus Episodic Treatment to Prevent Joint Disease in Boys with Severe
Hemophilia. MMJ NEJM 9 07.
- Low Risk of Inhibitor Formation in Haemophila Patients After a Change in Treatment
from Chinese Hamster Ovary Cell-Produced to Baby Hamster Kidney Cell-produced Recombinant
Factor VIII. Singleton E et al 2007.
Next: Patient Resources
»